PT-141 vs oxytocin for low sexual desire
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
| Aspect | Bremelanotide (PT-141) | Intranasal oxytocin | Source |
|---|---|---|---|
| Molecule and mechanism | Synthetic melanocortin receptor agonist (cyclic heptapeptide) | Cyclic nonapeptide hormone, oxytocin-receptor agonist; a different peptide family with a different target | source |
| FDA status | Approved as Vyleesi, NDA 210557, subcutaneous autoinjector | No approved nasal product (Syntocinon nasal discontinued); approved only as an injectable obstetric drug | source |
| Approved indication for desire | Acquired, generalized HSDD in premenopausal women, with labeled exclusions of postmenopausal women, men and performance enhancement | None for sexual function | source |
| Route and timing | 1.75 mg SC at least 45 minutes before anticipated activity; max 1 dose/24 h, 8/month | Nasal spray; the sexual-function trial used 32 IU within 50 minutes before intercourse | source |
| Best controlled result for sexual function | Two phase 3 RCTs: desire +0.30 to +0.42 vs placebo and distress improved; satisfying sexual events unchanged | 22-week randomized crossover in 30 women: FSFI rose 26% on oxytocin and 31% on placebo, no significant treatment effect | source |
| What it did not change | Satisfying sexual events; labeled as not for performance enhancement | Sexual drive, arousal, erection and lubrication unchanged at 24 IU in a couples study; secondary post-orgasm measures shifted | source |
| Key contraindication on the label | Uncontrolled hypertension or known cardiovascular disease | No nasal label exists; the injectable obstetric label governs a different use entirely | source |
Marketed to the same audience, these two peptides sit on opposite sides of the evidence ledger: bremelanotide holds an actual FDA approval for low desire in premenopausal women, with modest numbers it prints on its own label; intranasal oxytocin holds no approval for anything, and its best randomized sexual-function trial could not separate it from placebo.
An approved drug for a condition is not automatically the better choice for an individual, and an unapproved one is not automatically useless. What this table shows is asymmetry of evidence: one of these carries a labeled indication for low sexual desire with modest printed numbers, and the other has a randomized trial in which placebo matched it.
Researching Intranasal oxytocin itself? Its dedicated guide site is at oxytocinbio.com.